EGFR and peritoneum cancer: Cetuximab, a chimeric IgG1 monoclonal antibody that binds to the extracellular domain of EGFR, produced an objective response in 9 out of 26 patients when combined with carboplatin in patients with EGFR-positive ovarian or primary peritoneal cancer.